Inhalable drugs for systemic therapy.
Although oral and injectable drug formulations still dominate the market, interest in pulmonary delivery has been rising steadily. Given patients' desire for an alternative to injections, and recent advances in aerosol science and pulmonary medicine, the potential for improved disease management outcomes by using aerosols for systemic drug delivery should lead the way for a shift to inhalables.
Corkery
K
K
Inhale Therapeutic Systems, San Carlos, California 94070, USA. kcorkery@inhale.com
D000280:Administration, Inhalation; D000336:Aerosols; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000737:chemistry; D016503:Drug Delivery Systems; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D046911:Macromolecular Substances; D009330:Nebulizers and Vaporizers
D000336:Aerosols; D001993:Bronchodilator Agents; D005938:Glucocorticoids; D046911:Macromolecular Substances